Acute Myeloid Leukemia (non-APL) · line 2 · Revumenib monotherapy for R/R KMT2A-rearranged AML

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-REVUMENIB-AML`

ID	`IND-AML-2L-KMT2A-REVUMENIB`
Type	Indication
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ELN-AML-2022` `SRC-NCCN-AML-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for R/R KMT2A-rearranged AML. Bridge-to-alloHCT intent dominant. Ukraine access constraint dominant (not registered, FDA-only). Algorithm wiring deferred — not yet routed by ALGO-AML-2L (would require step-restructure to insert KMT2A branch; out of chunk scope). Bibliographic record SRC-AUGMENT-101 is available; clinical claim linkage requires dual clinical sign-off.

Used By

Algorithms

ALGO-AML-2L - ALGO-AML-2L

Red flag

RF-AML-KMT2A-ACTIONABLE - KMT2A rearrangement (MLL fusion at 11q23) in AML — ~5-10% prevalence in adult AML; ELN-20...